Label expansions in 2024 created new reimbursement pathways, leading to sharp increases in GLP1 use among Medicare patients, a population historically excluded from weightloss coverage
doi: 10.1186/s10194-023-01635-9 Summary Keywords insulin resistance, mitochondrial dysfunction, antioxidant defenses, oxidative stress, lipid metabolism Citation Sun W, Chen T, Song M, Gao Y and Xu S (2025) Energy metabolism disorders in migraine: triggers, pathways, and therapeutic repurposing
By Lana Pine | Published on June 24, 2026 4 min read The conversation around GLP-1 medications and appearance has largely centered on "Ozempic face," the gaunt, hollowed look that can accompany rapid weight loss
It also asks providers to counsel on realistic timelines, nausea, injection-site reactions and dehydration risk before a transition
supplier of research peptides